Avalanche Biotechnologies, Inc. and Lonza Announce Global Manufacturing Collaboration for Adeno-associated Viral Vectors for Gene Therapy

21-May-2012 - USA

Avalanche Biotechnologies, Inc. and Lonza announced a manufacturing collaboration focused on process development and scale-up efforts for the manufacturing of adeno-associated viral (AAV) vectors for gene therapy. AAV vectors are rapidly becoming one of the most promising gene delivery vehicles for the treatment of various diseases including inherited retinal disorders, age-related macular degeneration (AMD), hemophilia B, congestive heart failure, Parkinson’s disease and others.
 
As part of the agreement, Avalanche and Lonza will make the technology available to third parties and share in the revenue. The Avalanche/Lonza manufacturing collaboration will focus on the development and high-yield production of AAV vectors based on a novel technology that uses stable baculovirus. This technology was licensed by Avalanche from Virovek, who will also play a key role in the collaboration.
 
Terms of the agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances